Palonosetron
Palonosetron. Long-acting 5-HT3 antagonist — same target as ondansetron with 30× higher receptor affinity + 40h half-life. Single-dose efficacy… IV half-life 40 h.
Long-acting 5-HT3 antagonist — same target as ondansetron with 30× higher receptor affinity + 40h half-life. Single-dose efficacy through 5-day chemo-induced nausea window.
PK: THE RECORD THAT HOLDS UP. The half-life is verbatim twice over, the free fraction is verified from a verbatim binding percentage and honestly labelled review-grade, and the clearance the stored pair implies sits inside a verbatim published range. The feasibility identity is CORRECTLY NOT MANUFACTURED — for an intravenous-only record it degenerates into the clearance test — and the occupancy affinity was verified in the open-access full text exactly as its note claims, at a recombinant human receptor, so the free-fraction correction it receives is the right direction for that kind of measurement. The molecular weight is the free base, matching a dose expressed the same way, AND THE DOSE BLOCK IS RIGHT FOR A REASON WORTH RECORDING: the cited study dosed per kilogram while the stored figures are the actual FLAT LABEL doses, which is the opposite of the eleven records this batch found storing raw per-weight numbers. Only the volume is soft — inside two verbatim ranges but stated as a point value by nobody — and the arithmetic passes either way. ONE SOFT FLAG IS RANKED AS SOFT AND LEFT: a secondary paraphrase of a third paper reports late concentrations the model increasingly under-predicts, which is the signature of a terminal phase slower than the stored one, but it is a paraphrase of a secondary citation and this record own primary is satisfied.
Pharmacokinetics
- IV — t½ 40 h · F 100% · Vd 560 L
Sources: PMID:15102873, PMID:23581504, PMID:15139789